Peripheral serotonin levels as a predictor of antidepressant treatment response: A systematic review.
Prog Neuropsychopharmacol Biol Psychiatry
; 133: 111031, 2024 Jul 13.
Article
em En
| MEDLINE
| ID: mdl-38762162
ABSTRACT
There are currently no reliable biomarkers to predict clinical response to pharmacological treatments of depressive disorders. Peripheral blood 5-hydroxytryptamine (5-HT; serotonin) has been suggested as a biomarker of antidepressant treatment response, but there has not been an attempt to systematically summarize and evaluate the scientific evidence of this hypothesis. In this systematic review we searched MEDLINE, Embase, PsycINFO, and the Cochrane Central Register of Controlled Trials. Twenty-six relevant studies investigating peripheral 5-HT as an antidepressant biomarker were identified. In all, we did not find robust support for an association between baseline 5-HT and treatment response. Several larger studies with lower risk of bias, however, showed that higher baseline 5-HT was associated with a greater antidepressant response to SSRIs, prompting future studies to investigate this hypothesis. Our results also confirm previous reports that SSRI treatment is associated with a decrease in peripheral 5-HT levels; however, we were not able to confirm that larger decreases of 5-HT are associated with better treatment outcome as results were inconclusive.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Serotonina
/
Antidepressivos
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article